

PROVIDER Update



CONTRACTUAL | MAY 13, 2022 | UPDATE 22-375 | 3 PAGES

Stay Current with the Injectable Medication HCPCS/DOFR Crosswalk Reference Table – 2nd Quarter 2022

Use the updates for dates of service on and after July 19, 2022

On April 11, 2022, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective July 19, 2022, are listed on pages 2-3 of this Provider Update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 19 new injectable medications to be added to the DOFR crosswalk.
- 7 updates and changes to injectable medication procedure codes.

Additional information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider website at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Supports Providers
- Enhanced Care Management Providers

PROVIDER SERVICES

888-893-1569
www.healthnet.com

PROVIDER PORTAL

provider.healthnetcalifornia.com

Go to the online COVID-19 alerts page for info about COVID-19 vaccines!

At provider.healthnet.com > *COVID-19 Updates* > *Health Net Alerts*, you will find information about COVID-19 vaccines. This includes COVID-19 vaccine coverage details, how to enroll to administer the COVID-19 vaccine, and COVID-19 vaccine reporting and coding requirements. Also, access key tips you can use to help talk with and answer questions from your patients about the COVID-19 vaccine, especially those who are hesitant to receive it.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Adbry™	Tralokinumab-ldrm injection, for subcutaneous use	Therapeutic injection	
J3590	Carvykti™	Ciltacabtagene autoleucl suspension for intravenous infusion	Therapeutic injection	
J3590	Enjaymo™	Sutimlimab-jome injection, for intravenous use	Therapeutic injection	
J3490	Evusheld™	Tixagevimab 150 Mg/1.5ml & Cilgavimab 150 Mg/1.5ml IM Soln	Therapeutic injection	Immunization
J3590	Kimmtrak®	Tebentafusp-tebn IV soln 100 mcg/0.5m	Therapeutic injection	Chemotherapy ¹
J3490	Leqvio®	Inclisiran injection, for subcutaneous use	Therapeutic injection	
90619	Menquadfi™	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use	Therapeutic injection	Immunization
J3590	Releuko™	Filgrastim-ayow inj soln 300 mcg/ml	Self-injectable	Chemotherapy Adjunctive ¹
J3590	Ryplazim®	Plasminogen, human-tvmh	Therapeutic injection	
J3590	Skytrofa™	lonapegsomatropin-tcgd for injection, for subcutaneous use	Self-injectable	Growth hormone
J3590	Susvimo™	Ranibizumab injection) for intravitreal use (Ocular Implant)	Therapeutic injection	
J3590	Tezspire™	Tezepelumab-ekko injection, for subcutaneous use	Therapeutic injection	
J3590	Tivdak™	Tisotumab vedotin-tftv for injection 40 mg	Therapeutic injection	Chemotherapy ¹
J3590	Vabysmo™	Faricimab-svoa intravitreal inj 6 mg/0.05ml	Therapeutic injection	
90697	Vaxelis™	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use	Therapeutic injection	Immunization
J0248	Veklury®	Remdesivir, 1 mg	Therapeutic injection	

J3490	Voxzogo™	Vosoritide for injection, for subcutaneous	Self-injectable	
J3590	Vyvgart™	Efgartigimod alfa-fcab injection, for intravenous use	Therapeutic injection	
J3490	Xipere™	triamcinolone acetonide injectable suspension, for suprachoroidal use	Therapeutic injection	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9071	Cyclophosphamide	Injection, cyclophosphamide, (AuroMedics), 5mg, 10 mg	Replaces C9087
C9091	Fyarro™	Sirolimus protein-bound particles for IV	Replaces J3590
J2505	Neulasta® onpro®	6MG/0.6ML Solution J2506 Injection, pegfilgrastim,	Replaces J2506
J9293	Novantrone®	Mitoxantrone hydrochl / 5 MG	No longer Manufactured
S0148	Pegintron®	peginterferon alfa-2b	No longer Manufactured
J9999	Sylatron™	Peginterferon alfa-2b	No longer Manufactured
J3490	Tanzeum™	Albiglutide Injection	No longer Manufactured

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.